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Background/Aims: We compared the clinical and laboratory data between elderly 
and non-elderly patients with antineutrophil cytoplasmic antibody (ANCA)-as-
sociated vasculitis (AAV) at diagnosis; further, we investigated the predictors at 
diagnosis for all-cause mortality and end-stage renal disease (ESRD) occurrence 
during follow-up in Korean elderly patients with AAV. 
Methods: We reviewed the medical records of 191 AAV patients regarding clinical 
manifestations and laboratory results at diagnosis and during follow-up. The fol-
low-up duration was defined as the period from diagnosis to death for deceased 
patients or to the time of dialysis for ESRD patients, or to the last visit. Elderly (n 
= 67) and non-elderly (n = 124) patients were grouped based on an age threshold of 
65 years. 
Results: At diagnosis, elderly patients exhibited higher median Birmingham Vas-
culitis Activity Score (BVAS) and higher frequencies of ANCA positivity and pul-
monary manifestations than non-elderly patients. Furthermore, elderly patients 
exhibited increased median white blood cell count, blood urea nitrogen (BUN), 
alkaline phosphatase, erythrocyte sedimentation rate, and C-reactive protein and 
decreased median hemoglobin. However, there were no significant differences 
in all-cause mortality and ESRD occurrence between elderly and non-elderly 
patients. Meanwhile, elderly patients exhibited lower cumulative patients’ and 
ESRD-free survival rates than non-elderly patients. In the multivariable Cox haz-
ards model, BUN, creatinine and serum albumin at diagnosis were independent 
predictors for ESRD occurrence, whereas there were no independent predictors at 
diagnosis for all-cause mortality. 
Conclusions: Elderly AAV patients exhibited substantially higher rates of all-cause 
mortality and ESRD occurrence during follow-up compared than non-elderly 
AAV patients. 
Keywords: Antineutrophil cytoplasmic antibody-associated vasculitis; Aged; All-
cause mortality; End-stage renal disease; Predictor 
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INTRODUCTION
Antineutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis (AAV) is a group of systemic vasculitides in-
volving small vessels. On the basis of the 2012 Revised 
International Chapel Hill Consensus Conference No-
Received : February 4, 2020
Revised : March 6, 2020
Accepted : March 19, 2020
Correspondence to
Sang-Won Lee, M.D.
Division of Rheumatology, 
Department of Internal 
Medicine, Institute for 
Immunology and Immunological 
Diseases, Yonsei University 
College of Medicine, 50-1 Yonsei-








The Korean Journal of Internal Medicine Vol. 36, No. 3, May 2021
menclature of Vasculitides (the 2012 definitions), AAV is 
defined as vasculitis predominantly affecting small ves-
sels such as small intraparenchymal arteries, arterioles, 
capillaries, venules, and occasionally medium-sized ar-
teries and veins [1]. AAV can be further classified into 
three variants such as microscopic polyangiitis (MPA), 
granulomatosis with polyangiitis (GPA) and eosinophil-
ic granulomatosis with polyangiitis (EGPA) based on 
clinical manifestations and histological features such as 
necrotizing vasculitis, granulomas and eosinophilic in-
filtration [1,2]. Compared to other vasculitis, particularly 
Takayasu arteritis or immunoglobulin A vasculitis (He-
noch-Schonlein), AAV tends to occur in elderly people. 
Both MPA and GPA mainly occur in 60 to 70-year-old 
persons, whereas, EGPA often occurs in 40 to 60-year-
old persons [3].
To date, there have been several studies comparing 
the clinical features and outcomes of young and elder-
ly AAV patients: Early classification before advanced 
chronic kidney disease (CKD) and the use of immuno-
suppressive drugs improved the prognosis of AAV [4]; 
moreover, ESRD occurred more frequently in patients 
who were not treated with immunosuppressive drugs 
at 1 year after diagnosis. However, the rate of all-cause 
mortality was not different between the two groups [5]; 
elderly AAV patients exhibited higher incidence of both 
all-cause mortality and ESRD occurrence as well as the 
highest mortality rate within the first 6 months [6]. 
To the best of our knowledge, however, there is no re-
port yet on the comparative analysis of the clinical and 
laboratory features and the incidence of all-cause mor-
tality and ESRD occurrence in Korean elderly patients 
with AAV. Hence, in this study, we compared the clinical 
and laboratory features of elderly and non-elderly AAV 
patients at diagnosis and investigated the predictors at 
diagnosis for all-cause mortality and ESRD occurrence 
during follow-up in Korean elderly patients with AAV. 
METHODS
Patient population
We reviewed the medical records of 191 AAV patients 
according to the following inclusion and exclusion 
criteria: (1) patients should have been first classified as 
AAV at the Division of Rheumatology, Department of 
Internal Medicine, Yonsei University College of Med-
icine, Severance Hospital, between October 2000 and 
October 2018; (2) patients should have well-documented 
medical records to confirm their classification as MPA, 
GPA or EGPA and to assess both clinical manifestations 
at diagnosis and death during follow-up, and calculate 
Birmingham Vasculitis Activity Score (BVAS) and five 
factor score (FFS) at diagnosis. Because BVAS for GPA 
has a different weight-system from BVAS, we evenly ap-
plied BVAS to GPA to unify the scoring system [7-9]; (3) 
patients should meet the American College of Rheuma-
tology 1990 criteria and should be classified by the 2007 
European Medicines Agency algorithm and the 2012 
definitions [1,2]; (4) patients should have the results of 
perinuclear (P)-ANCA and cytoplasmic (C)-ANCA or my-
eloperoxidase (MPO)-ANCA and proteinase 3 (PR3)-AN-
CA. P-ANCA and C-ANCA were detected using an im-
munofluorescence assay and the titres of MPO-ANCA 
and PR3-ANCA were measured using an enzyme-linked 
immunosorbent assay [10]; (5) patients should have been 
followed up for 3 months or more; (6) patients should 
not have any serious medical conditions other than AAV, 
by which AAV activity and severity might be confused. 
Comorbidities at diagnosis or during follow-up were 
identified using the 10th revised International Classifi-
cation Diseases (ICD-10) and immunosuppressive drugs 
administered for AAV were verified by the Korean Drug 
Utilization Review system. We collated a list of 224 AAV 
patients, who had been classified as AAV and had AAV as 
the primary diagnosis from October 2000, via the Clin-
ical Data Repository System (CDRS) in November 2016. 
Of 224 AAV patients, 127 AAV patients fulfilled the in-
clusion criteria. In addition, from November 2016 to 3 
months before the entry of this study, 74 patients were 
newly classified as AAV and added to this study popu-
lation. Finally, 191 AAV patients were included in this 
study. This study was approved by the Institutional Re-
view Board of Severance Hospital (IRB No. 4-2017-0673), 
which waived the need for written informed consent 
from the patients, as this was a retrospective study.
Clinical and laboratory data at diagnosis 
At the time of AAV diagnosis, age and sex were com-
piled as demographic data. We calculated BVAS and FFS 
at diagnosis as AAV-specific indices. Clinical manifesta-
tions at diagnosis were recorded based on the items of 
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BVAS and FFS: general, cutaneous, muco-membranous/
ocular, ear nose throat, pulmonary, cardiovascular, gas-
trointestinal, renal, and nervous manifestations [7,9]. 
Routine laboratory data included positive ANCA types, 
white blood cell and platelet count, hemoglobin, fast-
ing glucose, blood urea nitrogen (BUN), creatinine, total 
serum protein, serum albumin, alkaline phosphatase 
(ALP), aspartate transaminase (AST), alanine transami-
nase (ALT), total bilirubin, erythrocyte sedimentation 
rate (ESR), and C-reactive protein (CRP). At diagnosis, 
the results of tests for autoantibodies were also reviewed 
to exclude autoimmune diseases other than AAV. 
Data during follow-up
During follow-up, all-cause mortality and ESRD were 
considered dependent variables in the prognosis anal-
ysis. In this study, patients, who received renal replace-
ment therapy before diagnosis, were not counted as 
ESRD during follow-up. The follow-up duration based 
on either all-cause mortality or ESRD was defined as the 
period between the date of the diagnosis of AAV and 
the date of the last visit for surviving patients or those 
without renal replacement. In the case of deceased pa-
tients, the follow-up duration based on all-cause mor-
tality was defined as the period between the diagnosis 
of AAV and the time of death. For patients who had 
ESRD, the follow-up duration for ESRD was defined as 
the period starting from the diagnosis of AAV until the 
initiation of renal replacement therapy. Comorbidities 
during follow-up included CKD (stage 3 to 5), diabetes 
mellitus, hypertension, interstitial lung disease (ILD), 
diffuse alveolar hemorrhage, ischemic heart disease, 
and cerebrovascular accident [3]. We also reviewed im-
munosuppressive drugs for AAV such as glucocorticoid, 
cyclophosphamide, rituximab, azathioprine, mycophe-
nolate mofetil, tacrolimus, methotrexate, and plasma 
exchange. 
Definition of an elderly AAV patient and severe AAV 
The median age at diagnosis of study population (n 
= 191) was 56.1 years with an interquartile range (IQR) 
of 21.0. We chose 65 years at diagnosis rather than 75 
years could be a better cut-off age for elderly AAV pa-
tients. When we defined an elderly AAV patient as a 
patient aged 65 years and above at the time of diagno-
sis [9], 124 patients comprised the non-elderly AAV pa-
tient-group and 67 patients comprised the elderly AAV 
patient-group. Additionally, we classified AAV patients 
aged 65 years or below at diagnosis as non-elderly AAV 
patients. We stratified AAV patients into three groups 
based on the tertile of BVAS and defined the lower limit 
of the highest tertile as the cut-off for severe AAV in the 
study (BVAS at diagnosis  ≥ 18).
Statistical analysis
All statistical analyses were conducted using IBM SPSS 
Statistics software version 23 for Windows (IBM Corp., 
Armonk, NY, USA). Continuous variables were expressed 
as a median and IQR, and categorical variables were ex-
pressed as number and percentage. We divided AAV pa-
tients into the two groups using the age of 65 years and 
above or below as the criterion and compared variables 
between two groups. Significant differences in categor-
ical variables between the two groups were analyzed us-
ing the chi-square and Fisher’s exact tests. Significant 
differences in continuous variables between the two 
groups were compared using the Mann-Whitney U test. 
Comparison of the cumulative patients’ and ESRD-free 
survival rate between the two groups were analyzed by 
the Kaplan-Meier survival analysis. In 67 patients with 
age ≥ 65 years, the multivariable Cox hazard model us-
ing variables with p value less than 0.05 and clinically 
relevant the hazard ratio (HR) in univariable Cox haz-
ard model was conducted to appropriately obtain HRs 
and determine the predictors for all-cause mortality and 
ESRD occurrence during the considerable follow-up 
duration. The p values less than 0.05 were considered 
statistically significant.
RESULTS 
Comparison of variables at diagnosis of elderly and 
non-elderly AAV patients based on an age cut-off of 
65 years 
The median ages of elderly and non-elderly AAV pa-
tients were 71.0 and 50.0 years, respectively. The pro-
portion of each AAV variant was evenly distributed in 
the two groups. MPO-ANCA (or P-ANCA) was detected 
more often in elderly AAV patients, whereas ANCA neg-
ative was observed more frequently in non-elderly AAV 
patients. Since FFS includes the age of 65 years or above 
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as one item of five factors, the median FFS in elderly 
AAV patients at diagnosis was inevitably larger than 
that in non-elderly AAV patients. Meanwhile, age is not 
a sub-item of BVAS. Nonetheless, the median BVAS in 
elderly AAV patients at diagnosis was higher than that in 
non-elderly AAV patients (14.0 vs. 11.5, p = 0.037). Among 
clinical manifestations at diagnosis, only the frequency 
of pulmonary manifestation meaningfully differed be-
tween elderly and non-elderly AAV patients (73.1% vs. 
48.4%, p = 0.001). Compared to non-elderly AAV patients, 
both elderly MPA patients and elderly GPA patients 
showed higher frequencies of pulmonary manifestation. 
However, elderly EGPA patients showed a frequency of 
pulmonary manifestation similar to that of non-elder-
ly EGPA patients. In this study, we counted five types 
of lung lesions at diagnosis: ILD, ground glass opacity, 
lung nodules, cavitary lesion, and migratory lung in-
filtration. There were no significant differences in five 
types of pulmonary manifestation between elderly and 
non-elderly AAV patients. Among routine laboratory re-
sults at diagnosis, elderly AAV patients exhibited higher 
median white blood cell count, fasting glucose, BUN, 
ALP, ESR, and CRP than non-elderly AAV patients. In 
contrast, elderly AAV patients had lower median hemo-
globin and serum albumin than non-elderly AAV pa-
tients (Table 1). There were no significant differences in 
the presence of autoantibodies between the two groups. 
Comparison of variables during follow-up of elderly 
and non-elderly AAV patients based on an age cut-
off of 65 years during follow-up 
Nine of 67 elderly AAV patients (13.4%) died, whereas 10 
of 124 non-elderly AAV patients (8.1%) died during fol-
low-up based on all-cause mortality. In addition, ESRD 
occurred in 14.9% of elderly AAV patients and 14.5% of 
non-elderly AAV patients during follow-up based on 
ESRD. Among the comorbidities during follow-up, el-
derly AAV patients exhibited higher frequency of CKD 
than non-elderly AAV patients (40.3% vs. 21.8%, p = 
0.007); however, patients in both groups showed simi-
lar frequencies of ESRD. Furthermore, the frequency of 
concurrent ILD in elderly AAV patients was much high-
er than that in non-elderly AAV patients (56.7% vs. 37.9%, 
p = 0.013). Glucocorticoid and immunosuppressive drugs 
were evenly administered to both groups (Table 2). 
Comparison of the cumulative patients’ and ES-
RD-free survival rates of elderly and non-elderly 
AAV patients based on an age cut-off of 65 years
To closely examine the differences in the cumulative 
patients’ and ESRD-free survival rates between the two 
groups considering the different median follow-up du-
rations, we conducted the Kaplan-Meier survival anal-
ysis. Elderly AAV patients exhibited lower cumulative 
patients’ survival rate than non-elderly AAV patients 
during follow-up based on all-cause mortality (p = 0.003) 
(Fig. 1A). Moreover, elderly AAV patients showed high-
er incidence of ESRD occurrence than non-elderly AAV 
patients during follow-up based on ESRD (p = 0.049) 
(Fig. 1B).  
Predictors at diagnosis for all-cause mortality 
during follow-up in elderly AAV patients 
To obtain independent predictors at diagnosis for all-
cause mortality during follow-up, we conducted the 
univariable and multivariable Cox hazard model anal-
yses. In the univariable Cox hazards model analysis, 
severe AAV (BVAS ≥ 18), hemoglobin, BUN, ALP, AST, 
and ALT at diagnosis were significantly associated with 
all-cause mortality in elderly AAV patients. However, 
no significant and independent predictors were found 
at diagnosis for all-cause mortality in the multivariable 
Cox hazards model analysis (Table 3). 
Predictors at diagnosis for ESRD occurrence during 
follow-up in elderly AAV patients 
We also analyzed the predictors for ESRD occurrence 
during follow-up using the univariable and multivari-
able Cox hazard model analysis. In the univariable Cox 
hazards model analysis, severe AAV, hemoglobin, BUN, 
creatinine, total serum protein, and serum albumin at 
diagnosis were significantly associated with all-cause 
mortality in elderly AAV patients. In general, total se-
rum protein is inversely correlated with renal dysfunc-
tion. However, in the univariable analysis, total serum 
protein exhibited a positive HR, which is not clinically 
relevant. Thus, we did not include total serum protein 
in the multivariable analysis despite its statistical signif-
icance. In the multivariable Cox hazards model analysis, 
BUN (HR, 1.073; 95% confidence interval [CI], 1.016 to 
1.133), creatinine (HR, 1.642; 95% CI, 1.132 to 2.383), and 
serum albumin (HR, 0.051; 95% CI, 0.006 to 0.444) were 
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Demographic data at diagnosis 
Age, yr 71.0 (67.0−75.0) 50.0 (40.0−58.0) < 0.001
Female sex 45 (67.2) 85 (68.5) 0.845
Variants at diagnosis 0.110
MPA 40 (59.7) 62 (50.0)
GPA 18 (26.9) 29 (23.4)
EGPA 9 (13.4) 33 (26.6)
ANCA positivity at diagnosis 
MPO-ANCA (or P-ANCA) 53 (79.1) 68 (54.8) 0.001
PR3-ANCA (or C-ANCA) 6 (9.0) 24 (19.4) 0.059
Both ANCAs 1 (1.5) 7 (5.6) 0.172
ANCA negativity 9 (13.4) 39 (31.5) 0.006
AAV-specific indices at diagnosis 
BVAS 14.0 (8.0−20.0) 11.5 (6.3−16.0) 0.037
FFS 2.0 (1.0−3.0) 1.0 (0−1.0) < 0.001
Clinical manifestations at diagnosis 
General 36 (53.7) 50 (40.3) 0.075
Cutaneous 10 (14.9) 33 (26.6) 0.065
Muco-membranous/ocular 3 (4.5) 9 (7.3) 0.450
Ear nose throat 26 (38.8) 48 (38.7) 0.990
Pulmonary 49 (73.1) 60 (48.4) 0.001
Interstitial lung disease 16 (23.9) 23 (18.5) 0.383
Ground glass opacity 19 (28.4) 24 (19.4) 0.155
Lung nodules 10 (14.9) 13 (10.5) 0.368
Cavitary lung lesions 5 (7.5) 6 (4.8) 0.458
Migratory lung infiltration 6 (9.0) 18 (14.5) 0.269
Cardiovascular 18 (26.9) 30 (24.2) 0.685
Gastrointestinal 3 (4.5) 7 (5.6) 0.730
Renal 45 (67.2) 67 (54.0) 0.079
Nervous 17 (25.4) 44 (35.5) 0.153
Routine laboratory results at diagnosis   
White blood cell count, /mm3 11,130.0 (7,700.0−14,500.0) 8,130.0 (5,912.5−11,392.5) < 0.001
Hemoglobin, g/dL 10.4 (9.1−12.6) 12.2 (10.1−13.4) 0.001
Platelet count, × 1,000/mm3 333.0 (230.0−433.0) 288.0 (228.3−373.0) 0.075
Fasting glucose, mg/dL 109.0 (93.0−129.0) 97.0 (89.0−115.0) 0.011
BUN, mg/dL 21.0 (15.2−42.6) 15.8 (10.8−25.0) < 0.001
Creatinine, mg/dL 1.0 (0.7−2.7) 0.9 (0.7−1.4) 0.141
Total serum protein, g/dL 6.4 (5.8−7.0) 6.7 (6.2−7.4) 0.136
Serum albumin, g/dL 3.2 (2.4−3.8) 3.8 (3.2−4.2) 0.036
ALP, IU/L 75.0 (60.0−106.0) 66.0 (50.3−88.8) 0.009
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AST, IU/L 18.0 (15.0−26.0) 18.0 (15.0−22.0) 0.635
ALT, IU/L 15.0 (10.0−21.0) 17.0 (12.3−26.0) 0.058
Total bilirubin, mg/dL 0.5 (0.3−0.6) 0.5 (0.4−0.6) 0.395
ESR, mm/hr 75.0 (40.0−107.0) 44.5 (20.0−82.5) < 0.001
CRP, mg/L 50.0 (2.9−112.4) 7.3 (1.0−36.9) < 0.001
Values are presented as median (interquartile range) or number (%). 
AAV, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; MPA, microscopic polyangiitis; GPA, granulomatosis 
with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; MPO, myeloperoxidase; P, perinuclear; PR3, pro-
teinase 3; C, cytoplasmic; BVAS, Birmingham Vasculitis Activity Score; FFS, five factor score; BUN, blood urea nitrogen; ALT, 
alkaline phosphatase; AST, aspartate transaminase; ALT, alanine transaminase; ESR, erythrocyte sedimentation rate; CRP, 
C-reactive protein. 
aElderly AAV patients was defined as those with an age ≥ 65 years, whereas non-elderly AAV patients was defined as those with 
an age < 65 years. 
Table 1. Continued









Prognosis during follow-up 
All-cause mortality 9 (13.4) 10 (8.1) 0.237
Follow-up duration based on all-cause mortality, mon 15.4 (6.2–59.0) 46.1 (13.1–104.2) < 0.001
ESRD 10 (14.9) 18 (14.5) 0.939
Follow-up duration based on ESRD, mon 15.4 (6.0–59.2) 44.2 (13.1–104.2) < 0.001
Comorbidities during follow-up 
CKD (stage 3–5) 27 (40.3) 27 (21.8) 0.007
Diabetes mellitus 17 (25.4) 21 (16.9) 0.163
Hypertension 34 (50.7) 48 (38.7) 0.109
ILD 38 (56.7) 47 (37.9) 0.013
Diffuse alveolar hemorrhage 2 (3.0) 7 (5.6) 0.408
Ischemic heart disease 7 (10.4) 6 (4.8) 0.142
Cerebrovascular accident 7 (10.4) 10 (8.1) 0.581
Immunosuppressive drugs
Glucocorticoid 62 (92.5) 105 (84.7) 0.118
Cyclophosphamide 25 (37.3) 55 (44.4) 0.347
Rituximab 5 (7.5) 15 (12.1) 0.318
Azathioprine 20 (29.9) 43 (34.7) 0.498
Mycophenolate mofetil 2 (3.0) 10 (8.1) 0.167
Tacrolimus 1 (1.5) 8 (6.5) 0.123
Methotrexate 2 (3.0) 12 (9.7) 0.090
Plasma exchange 3 (4.5) 3 (2.4) 0.436
Values are expressed as median (interquartile range) or number (%). 
AAV, antineutrophil cytoplasmic antibody-associated vasculitis; ESRD, end-stage renal disease; CKD, chronic kidney disease; 
ILD, interstitial lung disease. 
aElderly AAV patients was defined as those with an age ≥ 65 years, whereas non-elderly AAV patients was defined as those with 
an age < 65 years. 
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independent predictors at diagnosis for ESRD occur-
rence during follow-up based on ESRD in elderly AAV 
patients (Table 4).  
DISCUSSION
In this study, we compared clinical and laboratory data 
between elderly and non-elderly AAV patients. We first 
investigated the predictors at diagnosis for all-cause 
mortality and ESRD occurrence during follow-up in el-
derly AAV patients in a monocentric retrospective co-
hort in Korea and obtained several interesting findings. 
In the cross-sectional comparative analysis of variables 
at AAV diagnosis, elderly AAV patients exhibited high-
er median BVAS and higher frequencies of MPO-ANCA 
(or P-ANCA) positivity, ANCA positivity and pulmonary 
manifestations than non-elderly AAV patients. Further-
more, elderly AAV patients exhibited higher median 
white blood cell count, BUN, ALP, ESR, and CRP and 
lower median hemoglobin than non-elderly AAV pa-
tients. In the cross-sectional comparative analysis of 
variables during follow-up, elderly AAV patients exhib-
ited higher frequencies of CKD and ILD than non-el-
derly AAV patients. However, there were no significant 
differences in all-cause mortality and ESRD occurrence 
between elderly and non-elderly AAV patients.
With these results, we could make two assumptions. 
The first assumption is that highly active and severe 
AAV might occur more often in elderly people than in 
younger ones. The high median BVAS and increased 
frequencies of MPO-ANCA (or P-ANCA) and ANCA 
positivity in elderly AAV patients might support this 
assumption. Alternatively, even AAV, whose activity and 
severity are similar to those in non-elderly patients, 
could exaggerate the frequencies of AAV-specific man-
ifestations due to low daily functionality in elderly AAV 
patients, leading to an increase in BVAS. The second as-
sumption is that ageing itself might provoke enhanced 
autoimmunity and prolong autoinflammation. The 
detection rate of MPO-ANCA (or P-ANCA) is increased 
and the serological markers of chronic inflammation 
become apparent with age [5,11-14]. 
The Kaplan-Meier survival analysis revealed that el-
derly AAV patients exhibited lower cumulative patients’ 
and ESRD-free survival rates than non-elderly AAV pa-
tients, which were similar to the results of previous stud-
ies [4-6]. In addition, because the incidences of all-cause 
mortality and ESRD occurrence may gradually increase 
with age, if the age cut-off for elderly AAV patients is 
raised, would the difference be greater? The age cut-
off for elderly AAV patients was set at 75 years and the 
cumulative patients’ and ESRD-free survival rates were 
compared between the two groups. Similarly, elderly 
AAV patients exhibited lower cumulative patients’ and 
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Figure 1. (A, B) Comparison of the cumulative survival rates based on the age cut-off of 65 years. Elderly antineutrophil cyto-
plasmic antibody-associated vasculitis (AAV) patients (aged ≥ 65 years) exhibited lower cumulative patients’ and end-stage renal 
disease (ESRD)-free survival rates than non-elderly AAV patients (aged < 65 years). 
A B
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Table 3. Predictors at diagnosis for all-cause mortality during follow-up in elderly AAV patients (n = 67)
Variable
Univariable Multivariable
HR 95% CI p value HR 95% CI p value
Demographic data at diagnosis
Age 1.127 0.968–1.312 0.122
Female sex 0.366 0.091–1.469 0.156
Variants at diagnosis
MPA 2.53 0.529–12.317 0.243
GPA 0.894 0.180–4.429 0.890
EGPA 0.035 0.000–57.698 0.376
ANCA positivity at diagnosis
MPO-ANCA (or P-ANCA) 29.554 0.028–31,172.127 0.340
PR3-ANCA (or C-ANCA) 0.043 0.000–2,396.268 0.573
AAV-specific indices at diagnosis 
BVAS, ≥ 18 4.305 1.069–17.346 0.040 2.945 0.465–18.643 0.251
FFS, ≥ 2 4.078 0.509–32.685 0.186
Clinical manifestations at diagnosis 
General 0.501 0.120–2.096 0.344
Cutaneous 0.567 0.070–4.614 0.596
Muco-membranous/ocular 0.045 0.000–11,492.194 0.625
Ear nose throat 0.020 0.000–4.912 0.164
Pulmonary 3.518 0.402–30.750 0.256
Cardiovascular 3.279 0.878–12.243 0.077
Gastrointestinal 3.497 0.650–18.805 0.145
Renal 3.891 0.476–31.804 0.205
Nervous 0.833 0.172–4.025 0.820
Laboratory results at diagnosis   
White blood cell count 1.000 1.000–1.000 0.593
Hemoglobin 0.663 0.449–0.978 0.038 0.867 0.473–1.589 0.645
Platelet count 1.000 0.995–1.004 0.845
Fasting glucose 1.005 0.995–1.015 0.357
BUN 1.058 1.022–1.096 0.001 1.022 0.951–1.098 0.558
Creatinine 1.419 1.094–1.841 0.008 1.561 0.956–2.551 0.075
Total serum protein 0.612 0.263–1.424 0.254
Serum albumin 0.360 0.129–1.007 0.051
ALP 1.011 1.005–1.018 0.001 1.011 0.991–1.032 0.285
AST 1.028 1.002–1.005 0.035 1.197 0.985–1.456 0.071
ALT 1.017 1.003–1.032 0.017 0.880 0.761–1.019 0.087
Total bilirubin 3.429 0.604–19.447 0.164
ESR 1.013 0.994–1.032 0.171
CRP 1.005 0.994–1.015 0.393
AAV, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; HR, hazard ratio; CI, confidence interval; MPA, mi-
croscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; MPO, 
myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BVAS, Birmingham Vasculitis Activity Score; FFS, five 
factor score; BUN, blood urea nitrogen; ALP, alkaline phosphatase; AST, aspartate transaminase; ALT, alanine transaminase; 
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. 
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Table 4. Predictors at diagnosis for ESRD during follow-up in elderly AAV patients (n = 67) 
Variable
Univariable Multivariable
HR 95% CI p value HR 95% CI p value
Demographic data at diagnosis
Age 1.033 0.894–1.194 0.657
Female sex 0.700 0.174–2.809 0.615
Variants at diagnosis
MPA 3.235 0.683–15.323 0.139
GPA 0.743 0.154–3.580 0.711
EGPA 0.034 0.000–30.337 0.329
ANCA positivity at diagnosis
MPO-ANCA (or P-ANCA) 30.314 0.051–18,148.326 0.296
PR3-ANCA (or C-ANCA) 0.043 0.000–876.777 0.534
AAV-specific indices at diagnosis 
BVAS, ≥ 18 3.820 1.066–13.694 0.040 0.434 0.077–2.438 0.343
FFS, ≥ 2 42.806 0.201–9,125.277 0.170
Clinical manifestations at diagnosis 
General 2.862 0.594–13.787 0.190
Cutaneous 0.460 0.058–3.681 0.464
Muco-membranous/ocular 1.501 0.186–12.114 0.703
Ear nose throat 0.334 0.071–1.577 0.166
Pulmonary 1.091 0.267–4.459 0.903
Cardiovascular 0.639 0.136–3.016 0.572
Gastrointestinal 1.142 0.130–9.989 0.905
Renal 5.576 0.691–45.017 0.107
Nervous 1.227 0.316–4.762 0.767
Laboratory results at diagnosis   
White blood cell count 1.000 1.000–1.000 0.230
Hemoglobin 0.606 0.405–0.905 0.015 1.518 0.788–2.925 0.212
Platelet count 1.002 0.998–1.006 0.325
Fasting glucose 0.998 0.986–1.011 0.813
BUN 1.064 1.031–1.099 < 0.001 1.073 1.016–1.133 0.012
Creatinine 1.673 1.286–2.177 < 0.001 1.642 1.132–2.383 0.009
Total serum protein 1.057 1.001–1.117 0.047
Serum albumin 0.227 0.073–0.710 0.011 0.051 0.006–0.444 0.007
ALP 1.005 0.996–1.013 0.312
AST 0.939 0.846–1.042 0.234
ALT 0.950 0.867–1.040 0.266
Total bilirubin 0.123 0.002–6.110 0.293
ESR 1.004 0.988–1.021 0.609
CRP 1.005 0.995–1.015 0.325
AAV, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; HR, hazard ratio; CI, confidence interval; MPA, mi-
croscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; MPO, 
myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BVAS, Birmingham Vasculitis Activity Score; FFS, five 
factor score; BUN, blood urea nitrogen; ALP, alkaline phosphatase; AST, aspartate transaminase; ALT, alanine transaminase; 
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. 
740 www.kjim.org https://doi.org/10.3904/kjim.2020.039
The Korean Journal of Internal Medicine Vol. 36, No. 3, May 2021
but the statistical power was much higher (Supplemen-
tary Fig. 1). However, as mentioned in the Methods sec-
tion, the small number of elderly AAV patient could not 
warrant the statistical reliability. Therefore, we adopted 
the results of the comparative analysis of the cumulative 
survival rates between patients aged 65 years and above 
and those aged 65 years and below.
Regarding the predictors for ESRD occurrence during 
follow-up based on ESRD, BUN, creatinine and serum 
albumin at diagnosis were significant in the multivari-
able analysis. Because BUN and creatinine are variables 
directly associated with renal function, it could easily 
be accepted that the initial BUN and creatinine levels 
could predict the development of ESRD occurrence 
during AAV follow-up. Reduced serum albumin might 
be associated with persistent proteinuria, which can, in 
turn, accelerate renal function deterioration and finally 
provoke ESRD. Therefore, BUN, creatinine, and serum 
albumin at diagnosis could predict ESRD occurrence 
during follow-up based on ESRD regardless of the re-
lationship between these variables and the concurrent 
activity of AAV [15].
Additionally, we assessed predictors at diagnosis for 
all-cause mortality and ESRD in non-elderly AAV pa-
tients using the univariable and multivariable Cox haz-
ards model analysis; then we compared the differences 
between independent predictors for all-cause mortality 
and ESRD between elderly AAV patients and non-el-
derly AAV patients. Both elderly and non-elderly AAV 
patients showed no independent predictor for all-cause 
mortality (Supplementary Table 1). On the other hand, 
elderly AAV patients exhibited three independent pre-
dictors, such as BUN, creatinine, and serum albumin, 
whereas non-elderly AAV patients showed four inde-
pendent predictors, FFS ≥ 2, nervous manifestation, 
fasting glucose, and creatinine (Supplementary Table 2). 
Although it is difficult to determine the exact mecha-
nism of the differences between the two groups, we hy-
pothesize that the current activity of AAV at diagnosis 
may influence the progression to ESRD in non-elderly 
AAV patients, whereas advanced renal disease with low 
serum albumin at diagnosis may accelerate progression 
to ESRD in elderly AAV patients.
We believe that our study will contribute to under-
standing ethnic features in Korean elderly patients with 
AAV. We first demonstrated the cross-sectional differ-
ences in the clinical and laboratory features at diagno-
sis and prognosis as well as the comorbidities during 
follow-up between elderly and non-elderly AAV patients 
in Korea. Additionally, we provided information on 
the differences between the cumulative patients’ and 
ESRD-free survival rates based on the age cut-off of 65 
years and the initial independent predictors for all-
cause mortality and ESRD occurrence during follow-up 
based on each outcome in Korean patients with AAV. 
However, our study also has several limitations. First, 
since we reviewed medical records of AAV patients ret-
rospectively, we could not control the initial variables at 
AAV diagnosis and prevent missing data such as autoan-
tibodies related to other autoimmune connective tissue 
diseases, despite searching the concurrent diseases of 
each patient by ICD-10. Additionally, we could not col-
late the conventional risk factors for all-cause mortality 
at the time of diagnosis, such as medical history and du-
ration of diabetes mellitus, hypertension and dyslipid-
emia, smoking history, alcohol intake, and occupational 
factors. Concerning medications, the limitations of de-
tailed content in the medical records discouraged the 
authors from calculating the cumulative dose of each 
medication administered owing to the retrospective 
study design and patients’ compliance and adherence to 
the oral immunosuppressive drugs. For this reason, we 
had to count the number of patients who received each 
drug. Second, the number of patients in this study was 
not large enough to provide more validated and stronger 
evidence on the features of Korean elderly patients with 
AAV. Third, the number of AAV patients aged 75 years 
and above was only 20; therefore, we could not clearly 
analyze the clinical and laboratory features at diagnosis 
and prognosis as well as the comorbidities during fol-
low-up between patients aged 75 years and above and be-
low. Given that previous studies conducted in Western 
countries selected the age for elderly AAV patients as 75 
or 80 years, we could not compare the results of those 
previous studies with our results. Future multi-centric 
prospective studies with a large number of AAV patients, 
particularly more patients aged 75 years and above, will 
overcome these issues and provide more information 
on the features of Korean elderly patients with AAV. 
In conclusion, elderly AAV patients exhibited sub-
stantially higher rates of all-cause mortality and ESRD 
occurrence during follow-up than non-elderly AAV pa-
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tients. Furthermore, BUN, creatinine and serum albu-
min at diagnosis were independent predictors for ESRD 
during follow-up in Korean elderly patients with AAV. 
Conflict of interest
No potential conflict of interest relevant to this article 
was reported.
Acknowledgments
This research was supported by a grant from the Ko-
rea Health Technology R&D Project through the Ko-
rea Health Industry Development Institute, funded by 
the Ministry of Health and Welfare, Republic of Korea 
(HI14C1324).
REFERENCES
1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised Interna-
tional Chapel Hill Consensus Conference nomenclature 
of vasculitides. Arthritis Rheum 2013;65:1-11.
2. Watts R, Lane S, Hanslik T, et al. Development and vali-
dation of a consensus methodology for the classification 
of the ANCA-associated vasculitides and polyarteritis 
nodosa for epidemiological studies. Ann Rheum Dis 
2007;66:222-227.
3. Millet A, Pederzoli-Ribeil M, Guillevin L, Witko-Sarsat V, 
Mouthon L. Antineutrophil cytoplasmic antibody-asso-
ciated vasculitides: is it time to split up the group? Ann 
Rheum Dis 2013;72:1273-1279.
4. Weiner M, Goh SM, Mohammad AJ, et al. Outcome and 
treatment of elderly patients with ANCA-associated vas-
culitis. Clin J Am Soc Nephrol 2015;10:1128-1135.
5. Bomback AS, Appel GB, Radhakrishnan J, et al. ANCA-as-
sociated glomerulonephritis in the very elderly. Kidney 
Int 2011;79:757-764.
6. Hoganson DD, From AM, Michet CJ. ANCA vasculitis in 
the elderly. J Clin Rheumatol 2008;14:78-81.
7. Mukhtyar C, Lee R, Brown D, et al. Modification and val-
idation of the Birmingham Vasculitis Activity Score (ver-
sion 3). Ann Rheum Dis 2009;68:1827-1832.
8. Stone JH, Hoffman GS, Merkel PA, et al. A disease-specif-
ic activity index for Wegener’s granulomatosis: modifica-
tion of the Birmingham Vasculitis Activity Score. Interna-
tional Network for the Study of the Systemic Vasculitides 
(INSSYS). Arthritis Rheum 2001;44:912-920.
9. Guillevin L, Pagnoux C, Seror R, et al. The five-factor 
score revisited: assessment of prognoses of systemic nec-
rotizing vasculitides based on the French Vasculitis Study 
Group (FVSG) cohort. Medicine (Baltimore) 2011;90:19-27.
10. Csernok E, Moosig F. Current and emerging techniques 
for ANCA detection in vasculitis. Nat Rev Rheumatol 
2014;10:494-501.
11. Andres E, Serraj K, Federici L, Vogel T, Kaltenbach G. 
Anemia in elderly patients: new insight into an old disor-
der. Geriatr Gerontol Int 2013;13:519-527. 
12. Musch W, Verfaillie L, Decaux G. Age-related increase in 
plasma urea level and decrease in fractional urea excre-
tion: clinical application in the syndrome of inappro-
priate secretion of antidiuretic hormone. Clin J Am Soc 
Nephrol 2006;1:909-914.
13. Mukaiyama K, Kamimura M, Uchiyama S, Ikegami S, Na-
kamura Y, Kato H. Elevation of serum alkaline phospha-
tase (ALP) level in postmenopausal women is caused by 
high bone turnover. Aging Clin Exp Res 2015;27:413-418.
14. Bray C, Bell LN, Liang H, et al. Erythrocyte sedimentation 
rate and C-reactive protein measurements and their rele-
vance in clinical medicine. WMJ 2016;115:317-321.
15. Moon JS, Ahn SS, Park YB, Lee SK, Lee SW. C-reactive 
protein to serum albumin ratio is an independent pre-
dictor of all-cause mortality in patients with ANCA-asso-
ciated vasculitis. Yonsei Med J 2018;59:865-871.
KEY MESSAGE
1. Based on an age of 65 years, 67 of 191 antineu-
trophil cytoplasmic antibody (ANCA)-associat-
ed vasculitis (AAV) patients (35.1%) were classi-
fied as elderly patients.
2. Elderly AAV patients exhibited lower cumu-
lative patients’ and end-stage renal disease 
(ESRD) free survival rates than non-elderly AAV 
patients. 
3. Haemoglobin, blood urea nitrogen, creatinine, 
total protein and serum albumin at diagnosis 
were the independent predictors for ESRD in 
elderly AAV patients.
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Supplementary Table 1. Predictors at diagnosis for all-cause mortality during follow-up in non-elderly AAV patients (n = 124)
Variable
Univariable Multivariable
HR 95% CI p value HR 95% CI p value
Demographic data at diagnosis
Age 1.052 0.987–1.121 0.121
Female sex 0.508 0.146–1.771 0.288
Variants (MPA vs. GPA or EGPA) at diagnosis 0.473 0.121–1.854 0.283
ANCA positivity at diagnosis
MPO-ANCA (or P-ANCA) 0.748 0.188–2.974 0.680
PR3-ANCA (or C-ANCA) 2.766 0.783–9.767 0.114
AAV-specific indices at diagnosis 
BVAS, ≥ 18 1.063 0.219–5.147 0.943
FFS, ≥ 2 5.994 1.526–23.543 0.010 3.596 0.429–30.100 0.238
Clinical manifestations at diagnosis 
General 2.263 0.636–8.058 0.208
Cutaneous 0.122 0.015–1.022 0.052
Muco-membranous/ocular 1.092 0.213–5.592 0.916
Ear nose throat 1.973 0.546–7.120 0.300
Pulmonary 3.508 0.897–13.709 0.071
Cardiovascular 5.144 1.314–20.137 0.019 1.934 0.230–16.274 0.544
Gastrointestinal 1.084 0.134–8.735 0.940
Renal 9.993 1.221–81.807 0.032
Nervous 0.363 0.076–1.727 0.203
Laboratory results at diagnosis   
White blood cell count 1.000 1.000–1.000 0.458
Hemoglobin 0.945 0.713–1.251 0.691
Platelet count 0.999 0.994–1.004 0.689
Fasting glucose 1.002 0.984–1.021 0.795
BUN 1.000 0.981–1.019 0.999
Creatinine 0.946 0.735–1.218 0.667
Total serum protein 0.755 0.380–1.499 0.422
Serum albumin 0.651 0.271–1.568 0.339
ALP 1.000 0.992–1.009 0.937
AST 0.924 0.819–1.043 0.202
ALT 0.999 0.974–1.024 0.914
Total bilirubin 1.139 0.081–16.043 0.923
ESR 0.995 0.978–1.013 0.592
CRP 1.007 0.995–1.020 0.251
AAV, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; HR, hazard ratio; CI, confidence interval; MPA, mi-
croscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; MPO, 
myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BVAS, Birmingham Vasculitis Activity Score; FFS, five 
factor score; BUN, blood urea nitrogen; ALP, alkaline phosphatase; AST, aspartate transaminase; ALT, alanine transaminase; 
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. 
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Supplementary Table 2 Predictors at diagnosis for ESRD during follow-up in non-elderly AAV patients (n = 124)
Variable
Univariable Multivariable
HR 95% CI p value HR 95% CI p value
Demographic data at diagnosis
Age 1.028 0.985–1.073 0.207
Female sex 1.321 0.429–4.067 0.628
Variants (MPA vs. GPA or EGPA) at diagnosis 2.647 0.926–7.562 0.069
ANCA positivity at diagnosis
MPO-ANCA (or P-ANCA) 4.644 1.554–13.872 0.006 3.697 0.577–23.680 0.168
PR3-ANCA (or C-ANCA) 0.929 0.301–2.867 0.898
AAV-specific indices at diagnosis 
BVAS, ≥ 18 2.725 1.025–7.242 0.044 0.626 0.114–3.421 0.589
FFS, ≥ 2 3.349 1.269–8.839 0.015 6.875 1.168–40.470 0.033
Clinical manifestations at diagnosis
General 1.066 0.405–2.804 0.898
Cutaneous 0.389 0.123–1.234 0.109
Muco-membranous /Ocular 0.036 0.000–14.645 0.278
Ear nose throat 0.281 0.080–0.984 0.047 0.289 0.054–1.534 0.145
Pulmonary 2.676 0.980–7.305 0.055
Cardiovascular 2.197 0.842–5.729 0.108
Gastrointestinal 0.552 0.073–4.171 0.565
Renal 23.159 2.891–185.545 0.003 4.746 0.349–64.592 0.242
Nervous 0.211 0.048–0.930 0.040 0.084 0.007–0.964 0.047
Laboratory results at diagnosis   
White blood cell count 1.000 1.000–1.000 0.261
Haemoglobin 0.685 0.539–0.870 0.002 0.752 0.450–1.257 0.277
Platelet count 0.998 0.993–1.002 0.316
Fasting glucose 1.013 1.005–1.021 0.001 1.028 1.009–1.046 0.003
BUN 1.017 1.008–1.025 < 0.001 0.979 0.953–1.006 0.119
Creatinine 1.333 1.170–1.518 < 0.001 2.093 1.275–3.435 0.004
Total serum protein 0.650 0.380–1.115 0.118
Serum albumin 0.970 0.504–1.869 0.929
ALP 0.998 0.989–1.008 0.687
AST 0.921 0.842–1.007 0.069
ALT 0.955 0.903–1.010 0.106
Total bilirubin 0.165 0.010–2.799 0.212
ESR 1.004 0.992–1.016 0.497
CRP 1.003 0.993–1.014 0.539
AAV, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; HR, hazard ratio; CI, confidence interval; MPA, mi-
croscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; MPO, 
myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BVAS, Birmingham Vasculitis Activity Score; FFS, five 
factor score; BUN, blood urea nitrogen; ALP, alkaline phosphatase; AST, aspartate transaminase; ALT, alanine transaminase; 
ESR, erythrocyte sedimentation rate; CRP C-reactive protein. 
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Supplementary Figure 1. (A, B) Comparison of the cumulative survival rates based on the age of 75 years. Elderly antineutro-
phil cytoplasmic antibody-associated vasculitis (AAV) patients (aged ≥ 75 years) exhibited the lower cumulative patients’ and 
end-stage renal disease (ESRD)-free survival rates than non-elderly AAV patients (aged < 75 years), similar to the comparative 
analysis based on the age of 65 years. 
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